Dr. Lorenza Rimassa presents a five-year overall survival analysis from the Phase 3 HIMALAYA study, demonstrating sustained survival benefits of the STRIDE regimen versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).
Lorenza Rimassa, MD
Advertisement
Articles by Lorenza Rimassa, MD
Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).
Advertisement
Latest Updated Articles
Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRCPublished: July 4th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
5